The DOI matches its Crossref record; 482 of the 482 references it cites were found in a registry or an index.
The multi-factorial nature of clinical multidrug resistance in cancer
Abstract
Curative cancer therapy remains a major challenge particularly in cancers displaying multidrug resistance (MDR). The MDR phenotype is characterized by cross-resistance to a wide array of anticancer drugs harboring distinct structures and mechanisms of action. The multiple factors involved in mediating MDR may include host factors, tumor factors as well as tumor-host interactions. Among the host factors are genetic variants and drug-drug interactions. The plethora of tumor factors involves decreased drug uptake primarily via impaired influx transporters, increased drug efflux predominantly due to the overexpression of MDR efflux transporters of the ATP-binding cassette superfamily or due to drug efflux mediated by extracellular vesicles (EVs) or drug-loaded lysosomes undergoing exocytosis, deregulation of cell death mechanisms (i.e. anti-apoptotic modalities), enhanced DNA damage repair, epigenetic alterations and/or deregulation of microRNAs. The intratumor heterogeneity and dynamics, along with cancer stem cell plasticity, are important tumor factors. Among the tumor-host interactions are the role of the tumor microenvironment, selective pressure of various stressor conditions and agents, acidic pH and the intracellular transfer of traits mediated by EVs. The involvement of these diverse factors in MDR, highlights the need for precision medicine and real-time personalized treatments of individual cancer patients. In this review, written by a group of researchers from COST Action STRATAGEM "New diagnostic and therapeutic tools against multidrug resistant tumors", we aim to bring together these multidisciplinary and interdisciplinary features of MDR cancers. Importantly, it is becoming increasingly clear that deciphering the molecular mechanisms underlying anticancer drug resistance, will pave the way towards the development of novel precision medicine treatment modalities that are able to surmount distinct and well-defined mechanisms of anticancer drug resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Items 401–482 of 482
Plasma Exosome Profiling of Cancer Patients by a Next Generation Systems Biology Approach
Domenyuk, V., Zhong, Z., Stark, A., Xiao, N., O’Neill, H. A., Wei, X., Wang, J., Tinder, T. T., Tonapi, S. S., Duncan, J. E., et al. (2017) · Scientific Reports · doi:10.1038/srep42741 · Cited by 51
BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer
Pothuri, B. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt307 · Cited by 50
Calvisi, D. F., Pascale, R. M., & Feo, F. (2007) · Reviews on Recent Clinical Trials · doi:10.2174/157488707781662715 · Cited by 50
Grasse, S., Lienhard, M., Frese, S., Kerick, M., Steinbach, A., Grimm, C., Hussong, M., Rolff, J., Becker, M., Dreher, F., et al. (2018) · Genome Medicine · doi:10.1186/s13073-018-0562-1 · Cited by 50
Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer
Wong, G. L., Ha, V., Chu, M. P., Dersch‐Mills, D., Ghosh, S., Chambers, C. R., & Sawyer, M. B. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.11.001 · Cited by 50
Bad expression predicts outcome in patients treated with tamoxifen
Cannings, E., Kirkegaard, T., Tovey, S., Dunne, B., Cooke, T. G., & Bartlett, J. M. S. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9323-8 · Cited by 49
Dezentjé, V. O., van Schaik, R. H. N., Bogaartz, J. M. V. , van der Straaten, T., Wessels, J. A. M., Kranenbarg, E. M., Berns, E., Seynaeve, C., Putter, H., van de Velde, C. J. �., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2619-6 · Cited by 49
Wang, W., Zou, L., Zhou, D., Zhou, Z., Tang, F., Xu, Z., & Liu, X. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22376 · Cited by 47
Reversal of MRP7 (ABCC10)-Mediated Multidrug Resistance by Tariquidar
Sun, Y.-L., Chen, J.-J., Kumar, P., Chen, K., Sodani, K. S., Patel, A. S., Chen, Y., Chen, S.-D., Jiang, W.-Q., & Chen, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055576 · Cited by 47
Wang, Q., Shu, X., Dong, Y. Q., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15609 · Cited by 46
Advances in Precision Medicine: Tailoring Individualized Therapies
Matchett, K. B., Lynam‐Lennon, N., Watson, R. W. G., & Brown, J. A. L. (2017) · Cancers · doi:10.3390/cancers9110146 · Cited by 46
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma
Cucè, M., Cantafio, M. E. G., Siciliano, M. A., Riillo, C., Caracciolo, D., Scionti, F., Staropoli, N., Zuccalà, V., Maltese, L., Vito, A. D., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0714-9 · Cited by 46
Kearns, P. R., Pieters, R., Rottier, M. M. A., Pearson, A. D. J., & Hall, A. G. (2001) · Blood · doi:10.1182/blood.v97.2.393 · Cited by 45
Spitzwieser, M., Pirker, C., Koblmüller, B., Pfeiler, G., Hacker, S., Berger, W., Heffeter, P., & Cichna‐Markl, M. (2016) · Oncotarget · doi:10.18632/oncotarget.12332 · Cited by 45
Chan, E. W., Chiorean, E. G., O'Dwyer, P. J., Gabrail, N. Y., Alcindor, T., Potvin, D., Chao, R. C., & Hurwitz, H. I. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3494-3 · Cited by 45
Svedman, F. C., Lohcharoenkal, W., Bottai, M., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206942 · Cited by 45
Gemcitabine Cytotoxicity: Interaction of Efflux and Deamination
Rudin, D., Li, L., Niu, N., Kalari, K. R., & Gilbert, J. A. (2011) · Journal of Drug Metabolism & Toxicology · doi:10.4172/2157-7609.1000107 · Cited by 44
Altered primary chromatin structures and their implications in cancer development
Ferraro, A. (2016) · Cellular Oncology · doi:10.1007/s13402-016-0276-6 · Cited by 44
Li, Z., Chan, K., Qi, Y., Lu, L., Ning, F., Wu, M., Wang, H., Wang, Y., Cai, S., & Du, J. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2017.356 · Cited by 43
MiR-30a Decreases Multidrug Resistance (MDR) of Gastric Cancer Cells
Li, C., Zou, J., Zheng, G., & Chu, J.-K. (2016) · Medical Science Monitor · doi:10.12659/msm.898415 · Cited by 43
Su, F., Zhang, Y., Zhang, D., Zhang, Y., Pang, C., Huang, Y., Wang, M., Cui, L., He, L., Zhang, J., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.06.005 · Cited by 43
Ma, Y., Zhu, J., Chen, S., Li, T., Ma, J., Guo, S., Hu, J., Yue, T., Zhang, J., Wang, P., et al. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0599-7 · Cited by 43
Karachaliou, N., Cardona, A. F., Bracht, J. W. P., Aldeguer, E., Drozdowskyj, A., Fernández-Bruno, M., CHAIB-OUKADOUR, I., Berenguer, J., Santarpía, M., Ito, M., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.11.036 · Cited by 43
Anwar, M., Aslam, H. M., & Anwar, S. (2015) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-014-0024-8 · Cited by 43
Xie, J., Li, D., Chen, X., Wang, F., & Dong, P. (2013) · Oncology Letters · doi:10.3892/ol.2013.1321 · Cited by 42
Dong, H. P., Kleinberg, L., Silins, I., Flørenes, V. A., Trope, C. G., Risberg, B. Å., Nesland, J. M., & Davidson, B. (2007) · Cancer · doi:10.1002/cncr.23140 · Cited by 42
Alaoui‐Jamali, M. A., DUPRE, I., & Qiang, H. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2004.06.004 · Cited by 41
Zenke, Y., Yoh, K., Matsumoto, S., Umemura, S., Niho, S., Ohmatsu, H., Goto, K., & Ohe, Y. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.01.006 · Cited by 40
Vidula, N., Juric, D., Niemierko, A., Spring, L. M., Moy, B., Malvarosa, G., Yuen, M., Habin, K. R., Shin, J. A., Peppercorn, J. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.1020 · Cited by 40
Dhayat, S. A., Abdeen, B., Köhler, G., Senninger, N. J., Haier, J., & Mardin, W. A. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0166-1 · Cited by 39
Kjersem, J. B., Skovlund, E., Ikdahl, T., Guren, T. K., Kersten, C., Dalsgaard, A. M., Yilmaz, M., Fokstuen, T., Tveit, K. M., & Kure, E. H. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-340 · Cited by 38
Pérez-Ramírez, C., Cañadas‐Garre, M., Molina‐Vila, M. Á., Robles, A. I., Faus-Dáder, M. J., & Calleja‐Hernández, M. Á. (2016) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2016.11.003 · Cited by 38
Sharma, A. R., Vatapalli, R. J., Abdelfatah, E., McMahon, K. W., Kerner, Z. J., Guzzetta, A. A., Singh, J., Zahnow, C. A., Baylin, S. B., Yerram, S. R., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176139 · Cited by 38
Gao, X., Zhang, L., Wei, Y., Yang, Y., Li, J., Wu, H., & Yin, Y. (2019) · Journal of Cancer · doi:10.7150/jca.28229 · Cited by 38
Ueno, T., Saji, S., Sugimoto, M., Masuda, N., Kuroi, K., Sato, N., Takei, H., Yamamoto, Y., Ohno, S., Yamashita, H., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2270-9 · Cited by 37
Pérez-Ramírez, C., Cañadas‐Garre, M., Alnatsha, A., Villar, E., Valdivia-Bautista, J., Faus-Dáder, M. J., & Calleja‐Hernández, M. Á. (2018) · The Pharmacogenomics Journal · doi:10.1038/s41397-018-0014-8 · Cited by 37
Ponnusamy, L., Mahalingaiah, P. K. S., Chang, Y.-W., & Singh, K. P. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.07.028 · Cited by 37
Henríquez, J. A., Sleeman, J. P., & Garvalov, B. K. (2018) · Clinical & Experimental Metastasis · doi:10.1007/s10585-018-9930-x · Cited by 37
Tang, R., Lei, Y., Hu, B., Yang, J., Fang, S., Wang, Q., Li, M., & Guo, L. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.186 · Cited by 36
Dissecting PARP inhibitor resistance with functional genomics
Pettitt, S. J., & Lord, C. J. (2019) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2019.03.001 · Cited by 34
Chu, Y., Li, H., Tan, H. S., Koh, V. C. Y., Lai, J. C. H., Phyo, W. M., Choudhury, Y., Kanesvaran, R., Chau, N. M., Toh, C., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134102 · Cited by 33
Costa, A. F. O., Menezes, D., Pinheiro, L. H. S., Sandes, A. F., Nunes, M. A. P., de Lyra, D. P., & Schimieguel, D. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-00816-2 · Cited by 33
Chen, X., Li, Y., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., Lin, B., & Xie, Y. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy338 · Cited by 33
Feedback networks between microRNAs and epigenetic modifications in urological tumors
Liep, J., Rabien, A., & Jung, K. (2012) · Epigenetics · doi:10.4161/epi.19464 · Cited by 32
Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004–2010
Dusetzina, S. B., Alexander, G. C., Freedman, R. A., Huskamp, H. A., & Keating, N. L. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2330-z · Cited by 31
Zhang, Y., Mei, Q., Liu, Y., Li, X., Brock, M. V., Chen, M., Dong, L., Shi, L., Wang, Y., Guo, M., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1323619 · Cited by 30
Intratumor genetic heterogeneity in squamous cell carcinoma of the oral cavity
Zandberg, D. P., Tallon, L. J., Nagaraj, S., Sadzewicz, L., Zhang, Y., Strome, M. B., Zhao, X., Vavikolanu, K., Zhang, X., Papadimitriou, J. C., et al. (2019) · Head & Neck · doi:10.1002/hed.25719 · Cited by 30
Are BRCA1 and BRCA2 gene mutation patients underscreened for pancreatic adenocarcinoma?
Roch, A. M., Schneider, J., Carr, R. A., Lancaster, W. P., House, M. G., Zyromski, N. J., Nakeeb, A., Schmidt, C. M., & Ceppa, E. P. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25376 · Cited by 29
Hong, J. Y., Liu, X., Mao, M., Li, M., Choi, D. I., Kang, S. W., Lee, J., & Choi, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069752 · Cited by 29
Somatic pharmacogenomics in cancer
Ikediobi, O. N. (2008) · The Pharmacogenomics Journal · doi:10.1038/tpj.2008.8 · Cited by 29
García-Domínguez, D. J., Hontecillas‐Prieto, L., Rodríguez‐Núñez, P., Pascual‐Pasto, G., Vilà-Ubach, M., García-Mejías, R., Robles, M. J., Tirado, Ò. M., Mora, J., Carcaboso, A. M., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25829 · Cited by 29
Bani, M. R., Decio, A., Giavazzi, R., & Ghilardi, C. (2017) · Angiogenesis · doi:10.1007/s10456-017-9549-6 · Cited by 28
Tumor Oxygenation Status: Facts and Fallacies
Vaupel, P. W., & Mayer, A. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55231-6_13 · Cited by 28
Siegelmann‐Danieli, N., Kurnik, D., Lomnicky, Y., Vesterman‐Landes, J., Katzir, I., Bialik, M., & Loebstein, R. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1008-7 · Cited by 27
Li, D., Zhou, L. F., Huang, J., & Xiao, X. (2016) · Oncology Letters · doi:10.3892/ol.2016.4749 · Cited by 27
Intracellular pH dynamics and charge-changing somatic mutations in cancer
White, K. A., Kisor, K. P., & Barber, D. L. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09791-8 · Cited by 27
Domenyuk, V., Gatalica, Z., Santhanam, R., Wei, X., Stark, A., Kennedy, P., Toussaint, B., Levenberg, S., Wang, J., Xiao, N., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03631-z · Cited by 26
Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance
SUN, Y.-L., Kathawala, R. J., Singh, S., Zheng, K., Talele, T. T., Jiang, W.-Q., & Chen, Z. (2012) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328354a196 · Cited by 25
Hennig, E. E., Piątkowska, M., Karczmarski, J., Goryca, K., Brewczynska, E., Jaźwiec, R., Kluska, A., Omiotek, R., Paziewska, A., Dadlez, M., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1575-4 · Cited by 24
Tarasov, V. V., Chubarev, V. N., Ashraf, G. M., Dostdar, S. A., Sokolov, A. V., Melnikova, T. I., Sologova, S. S., Grigorevskikh, E., Makhmutovа, A., Kinzirsky, A. S., et al. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190305130141 · Cited by 23
Advancing Drug Development in Gynecologic Malignancies
Beaver, J. A., Coleman, R. L., Arend, R. C., Armstrong, D. K., Bala, S., Mills, G. B., Sood, A. K., & Herzog, T. J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0619 · Cited by 23
Staiger, A. M., Duppel, J., Dengler, M. A., van der Kuip, H., Vöhringer, M. C., Aulitzky, W. E., Rosenwald, A., Ott, G., & Horn, H. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1263841 · Cited by 22
MicroRNA-21 contributes to the discrimination of chemoresistance in metastatic gastric cancer
Qi, M., Liu, D., & Zhang, S. (2017) · Cancer Biomarkers · doi:10.3233/cbm-161732 · Cited by 22
Goričar, K., Kovač, V., & Dolžan, V. (2017) · Scientific Reports · doi:10.1038/srep46537 · Cited by 22
Rinaldetti, S. L., Pfirrmann, M., Manz, K. M., Guilhot, J., Dietz, C., Panagiotidis, P., Spieß, B., Seifarth, W., Fabarius, A. C., Müller, M. C., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.02.004 · Cited by 22
Yang, Y., Hu, J., Selby, C. P., Li, W., Yimit, A., Jiang, Y., & Sancar, A. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006121 · Cited by 22
Li, N., Liu, Y. M., Pang, H., Lee, D., Zhou, Y., & Xiao, Z. (2019) · Medical Science Monitor · doi:10.12659/msm.911862 · Cited by 22
Wang, D., Patel, A. S., Sim, H., Zhang, Y.-K., Wang, Y., Kathawala, R. J., Zhang, H., Talele, T. T., Ambudkar, S. V., Xu, R., et al. (2014) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24787 · Cited by 20
A possible role for oxidation stress in lymphoid leukaemias and therapeutic failure
Sarmento‐Ribeiro, A. B., Proença, M. T., Sousa, I., Pereira, A., Guedes, F., Teixeira, A., & Oliveira, C. R. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.03.015 · Cited by 18
Self-citationZhang, L., Zhao, J., Yu, B., Song, X., Sun, G., Han, L., Wang, L., & Dong, S. (2017) · Cancer Genetics · doi:10.1016/j.cancergen.2017.09.004 · Cited by 18
Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma
Hamieh, L., Choueiri, T. K., Ogórek, B., Khabibullin, D., Rosebrock, D., Livitz, D. G., Fay, A. P., Pignon, J., McDermott, D. F., Agarwal, N., et al. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007679 · Cited by 18
Lai, C.-Y., Hsieh, L.-L., Sung, F.-C., Tang, R., Bai, C., Wu, F.-Y., Chiou, H., & Yeh, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069039 · Cited by 17
Beheshti, F., Hassanian, S. M., Khazaei, M., Hosseini, M., Shahidsales, S., Hasanzadeh, M., Maftouh, M., Ferns, G. A., & Avan, A. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26091 · Cited by 16
Przybilla, J., Hopp, L., Lübbert, M., Loeffler, M., & Galle, J. (2017) · Epigenetics · doi:10.1080/15592294.2017.1361090 · Cited by 16
Farmanbar, A., Firouzi, S., Makałowski, W., KNELLER, R. W., Iwanaga, M., Utsunomiya, A., Nakai, K., & Watanabe, T. (2018) · Neoplasia · doi:10.1016/j.neo.2018.07.001 · Cited by 16
Adaptive mechanisms of resistance to anti-neoplastic agents
Ferreira, B. I., Lie, M. K., Engelsen, A. S. T., Machado, S., Link, W., & Lorens, J. B. (2016) · MedChemComm · doi:10.1039/c6md00394j · Cited by 14
Takada, M., Nagai, S. E., Haruta, M., Sugino, R. P., Tozuka, K., Takei, H., Ohkubo, F., Inoue, K., Kurosumi, M., Miyazaki, M., et al. (2017) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22445 · Cited by 14
Sun, Z., Liu, J., Jing, H., Dong, S., & Wu, J. (2017) · Oncotarget · doi:10.18632/oncotarget.19408 · Cited by 14
(2015) · Cancer Cell & Microenvironment · doi:10.14800/ccm.807 · Cited by 11
Ürün, Y., Yaşar, A., Turna, H., Esin, E., Sedef, A. M., Alkan, A., Öksüzoğlu, B. Ç., Özdemir, N., Sendur, M. N., Sezer, A., et al. (2018) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155218805539 · Cited by 10
Rodríguez-Balada, M., Roig, B., Melé, M., Salvat, M., Martorell, L., Borràs, J., & Gumà, J. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1837-0 · Cited by 8
Yao, Y., He, Y., Han, X., Ji, C., & Hu, B. (2018) · Oncology Letters · doi:10.3892/ol.2018.8894 · Cited by 2
Cited by
Extracellular vesicles as tools and targets in therapy for diseases
Kumar, M. A., Baba, S. K., Sadida, H. Q., Marzooqi, S. A., Jerobin, J., Altemani, F. H., Algehainy, N., Alanazi, M. A., Abou-Samra, A.-B., Kumar, R., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01735-1 · Cited by 1,343
Erin, N., Grahovac, J., Brozovic, A., & Efferth, T. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100715 · Cited by 527
Self-citationAnticancer drug resistance: An update and perspective
Nussinov, R., Tsai, C.-J., & Jang, H. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100796 · Cited by 386
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming
Mosca, L., Ilari, A., Fazi, F., Assaraf, Y. G., & Colotti, G. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100742 · Cited by 385
Self-citationApoptosis Deregulation and the Development of Cancer Multi-Drug Resistance
Neophytou, C. M., Trougakos, I. P., Erin, N., & Papageorgis, P. (2021) · Cancers · doi:10.3390/cancers13174363 · Cited by 371
Metadata
- Authors
- Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2019-09
- Volume
- 46
- Pages
- 100645
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W2974459221
- Cited by
- 528
- References
- 482
- FWCI
- 21.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.